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The ability to increase energy expenditure by burning fats for heat production is a 
specialized characteristic of mammals that allows for maintenance of core body 
temperature in cold environments. The molecular mechanisms involved in thermogenesis 
include the actions of uncoupling proteins which facilitate inefficient conversion of 
nutrients into cellular energy allowing energy dissipation in the form of heat. Increased 
energy expenditure resulting from increased uncoupling protein 3 (UCP3) expression in 
skeletal muscle and adipose tissue can prevent obesity and lower body weight. Here, we 
demonstrate that UCP3 overexpression in basal epidermis is sufficient to prevent obesity 
and lower body weight. Furthermore, overexpression of UCP3 in epidermis increases 
overall glucose tolerance and insulin sensitivity through activation of the energy sensitive 
kinase, AMP-activated kinase (AMPK) and increased expression of the glucose 
transporter, Glut1.  This provides a proof-of-principle that uncoupled respiration in skin 
may be a useful target in treating obesity and hyperglycemia.  
 vi 
UCP3 overexpression increases lipid oxidation in epidermis that opposes 
accumulation of biomass needed for keratinocyte proliferation.  Studies within provide a 
link between increased lipid catabolism and inhibition of Akt as a new mechanism of 
metabolic regulation of cell signaling.  UCP3-mediated lipid oxidation leads to altered 
membrane dynamics and reduced membrane localization of Akt.  Inhibition of lipid 
oxidation rescues Akt activation when UCP3 is overexpressed and activates Akt in 
normal murine and human keratinocytes. Overexpression of Akt rescues proliferation and 
carcinogenesis in the presence of UCP3 overexpression in bitransgenic mice. These 
findings demonstrate that UCP3 overexpression can limit cell proliferation and 
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Chapter 1:  Introduction 
1.1 MECHANISMS OF BODY WEIGHT REGULATION 
Overall body weight is controlled by the balance of energy intake and energy 
expenditure.  Energy intake in excess of energy expenditure leads to weight gain and long 
term leads to obesity.  With obesity rates rising at an alarming rate, the need for novel 
therapeutic alternatives to reverse obesity and prevent consequential disease progression 
has never been greater.  Over the past decade, genetic studies have greatly advanced our 
knowledge of mechanisms that regulate body weight.  This has enhanced the 
development of therapeutics that target limiting energy intake or nutrient absorption, 
altering protein and fat storage, or increasing energy expenditure1.  Fat storage evolved as 
a mechanism to protect body weight when energy intake is low, so many anti-obesity 
treatments reach a plateau of efficacy after an initial weight loss, as the body attempts to 
maintain metabolic homeostasis and fight further weight loss.  This has increased interest 
in thermogenic mechanisms that increase fat oxidation and may be used in conjunction 
with current therapies.  Here, I will present data suggesting that disruption of epidermal 
lipid metabolism can increase energy expenditure to reduce body weight and prevent 
obesity. 
Total energy expenditure is comprised of the energy needed to maintain cellular 
adenosine triphosphate (ATP) levels or basal metabolic rate, and thermogenesis in which 
fat is burned for heat production.  Basal metabolic rate can be increased with activity, and 
regular exercise has been promoted as a mechanism to increase basal metabolic rate and 
energy expenditure.  However, the high caloric content of modern diets makes exercise 
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alone insufficient to combat obesity long term without dietary intervention.  Interestingly, 
mechanisms that increase energy expenditure through thermogenesis have consistently 
demonstrated sufficiency to decrease body weight even with obesogenic diets2,3.  A brief 
review of systemic metabolic regulation and cellular energy production follows to help 
explain our findings that increased energy expenditure in basal epidermis can lower body 
weight.  
1.2 MECHANISMS OF ENERGY STORAGE  
The rate of energy expenditure must be matched by homeostatic control of circulating 
nutrient availability and energy storage.  In between feeding, animals maintain relatively 
tight circulating glucose levels even upon days of fasting that is achieved by release of 
energy stores from adipose tissue and hepatic glucose production.  Energy storage and 
release is regulated through a complex network of metabolic hormones that modulate 
multiple organ systems simultaneously4-6. This subject has been reviewed elsewhere, so a 
brief discussion of the role of insulin in regulating fat storage and glucose homeostasis 
follows.  
After a 24 hour fast, circulating insulin levels are low and blood glucose 
concentration is maintained by hepatic glucose production which matches glucose 
utilization by peripheral tissues.  Adipose tissue undergoes lipolysis during fasting to 
release of free fatty acids that can be taken up by tissues that utilize β-oxidative 
pathways.  After a meal, blood glucose levels rise and insulin is released, which promotes 
energy storage through both excitatory and inhibitory actions various tissues.  In skeletal 
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muscle, insulin stimulates glucose uptake through glucose transporter 4 (GLUT4) to 
replenish local glycogen stores and stimulates protein synthesis.  In adipose tissue, insulin 
stimulation also increases glucose uptake through GLUT4 to increase de novo lipogenesis 
and fat storage.  Additionally, insulin inhibits adipose lipolysis, and promotes adipocyte 
proliferation to increase fat storage capacity.  In liver, insulin stimulation inhibits 
gluconeogenesis and promotes glycogen and fatty acid synthesis.  Liver converts excess 
glucose into triglycerides that can be transported to adipose tissue for long term storage. 
These mechanisms of energy storage (summarized in Illustration 1)  are 
dysregulated in Type 2 diabetes and result in hypoglycemia and hyperinsulinemia due to 
insulin resistance7.  Increased thermogenesis has beneficial effects on whole body 
metabolism by improved glucose tolerance and insulin sensitivity reduced fat 
accumulation2,8.  Thermogenic mechanisms that promote this effect function at the level 
of mitochondria reducing the efficiency of ATP production, driving increased nutrient 
demand by thermogenic tissues. 
1.2 MECHANISMS OF ENERGY PRODUCTION  
 
Generally, cells utilize glucose or free fatty acids derived from circulation to 
produce energy in the form of ATP in mitochondria.  Many tissues contain cells that can 
switch from glucose oxidation to fatty acid oxidation when glucose levels are low (e.g. 




Illustration 1. Mechanisms of energy storage by insulin 
Insulin negatively controls circulating glucose levels by inhibiting hepatic glucose 
production and promoting fatty acid synthesis in liver.  In white adipose tissue, insulin 
inhibits lipolysis and free fatty acid (FFA) release and promotes energy storage by 
increasing lipogenesis and triglyceride synthesis.  In skeletal muscle, insulin stimulation 

































production when circulating glucose is increased (e.g. feeding).  Glucose enters cells 
through glucose transport proteins (GLUTs) at the cell membrane and is oxidized using 
the glycolytic pathway converting the 6 carbon sugar into (2) 3 carbon intermediates of 
pyruvate, generating a net 2 ATP in the process9.  Pyruvate is a versatile intermediate that 
can be completely oxidized to carbon dioxide (CO2) in mitochondria, converted to lactate 
and secreted from the cell, or utilized for biosynthetic reactions.  Pyruvate destined for 
energy production enters the mitochondria through the mitochondrial pyruvate carrier 
(MPC) and is converted into acetyl CoA by the actions of pyruvate dehydrogenase 
(PDH)10.  Mitochondrial acetyl CoA can also be produced through β-oxidation of fatty 
acids.   Fatty acids stored as triglycerides in adipose tissue are released upon fasting or in 
times of high energy demand (e.g. cold exposure, exercise).  Cells in peripheral tissues 
import fats from circulation using membrane transport proteins (CD36/FATp) and into 
mitochondria using the mitochondrial carnitine shuttle6. Carnitine palmitoyl-transferase 1 
(CPT1) conjugates a fatty acyl-CoA to carnitine to produce an acyl-carnitine which can 
be transported into the mitochondrial matrix by a translocase where carnitine palmitoyl 
transferase 2 (CPT2) converts the acyl-carnitine back to a fatty acyl-CoA and free 
carnitine.  The fatty acyl-CoA can then enter the β-oxidation pathway to generate acetyl 
CoA, and the free carnitine is transported out of the matrix for continued utilization by 





Illustration 2. The carnitine shuttle for mitochondrial fatty acid import 
Fatty acyl CoA is conjugated to carnitine by carnitine palmitoyltransferase 1 (CPT1) on 
the outer mitochondrial membrane.  The outer membrane is permeable to acyl-carnitines 
which are then transported into the mitochondrial matrix by a translocase where carnitine 
palmitoyltransferase 2 (CPT2) then removes the carnitine and releases a free fatty acyl 
CoA into the mitochondrial matrix where it can enter the β-oxidation pathway.  The 













Acetyl CoA generated from either pyruvate or fatty acid oxidation enters the TCA cycle 
and combines with oxaloacetate to generate citrate.  Citrate is a 6 carbon intermediate 
that can be oxidized using the tricarboxylic acid (TCA) cycle to produce reduced high 
energy carriers, nicotinamide adenine dinucleotide (NADH) and Flavin adenine 
dinucleotide (FADH2).  These reduced intermediates are then oxidized to NAD+ and FAD 
respectively, and donate electrons to the electron transport chain (ETC, also called 
mitochondrial respiratory chain) in the inner mitochondrial membrane.  The oxidation of 
NADH and FADH2 donates electrons to complexes I and II of the ETC and electrons are 
passed down an electronegativity gradient to the final electron acceptor, molecular 
oxygen, which is quickly converted into water. This consumption of oxygen is commonly 
referred to as mitochondrial respiration and can be measured directly to investigate ETC 
function12. As electrons are transferred, members of the electron transport chain pump 
protons from the mitochondrial matrix into the intermembrane space building up a proton 
gradient. This proton gradient generates mitochondrial membrane potential and is the 
proton motive force which drives ATP synthesis coupling nutrient oxidation to ADP 
phosphorylation (Illustration 3).  
Oxidative phosphorylation can be circumvented by proton leak in which protons 
pass down the gradient independent of ATP production resulting in energy lost as heat 
(thermogenesis).   Proton leak lowers mitochondrial membrane potential which leads to 
an increase in ETC flux and mitochondrial respiration in effort to restore the gradient.  
This uncoupled respiration is no longer linked to ATP phosphorylation thus to maintain 
the same levels of ATP, cells must oxidize more nutrients and energy expenditure is 
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increased. The physiological role of uncoupled respiration is best understood in 
temperature regulation. Environmental temperatures below an organism’s thermoneutral 
point induce thermogenic mechanisms in which fat stores are oxidized to produce heat by 
uncoupled respiration13.  Proton leak can also be induced by chemical uncouplers like 2-
4-dinitrophenol (DNP) leading to increased energy expenditure14.  This mechanism has 
been linked to weight loss since the 1930s when DNP was approved by the FDA as a 
weight loss therapeutic; however, the drug proved to have a relatively narrow therapeutic 
window with fatal consequences and was subsequently removed from the market. This 
led to research focused on understanding uncoupling proteins, the endogenous mediators 




Illustration 3.  Mitochondrial TCA cycle and electron transport chain 
Acetyl CoA generated from pyruvate or fatty acid oxidation enters the TCA cycle by 
condensing with oxaloacetate to form citrate.  The oxidation of citrate in the TCA cycle 
regenerates oxaloacetate and generates NADH and FADH2 in the mitochondrial matrix.  
NADH and FADH2 are then oxidized and donate electrons to the electron transport chain 
at complexes I and II. Electrons are passed down an electronegativity gradient which 
allows complexes of the electron chain to transport protons from the mitochondrial 
matrix into the intermembrane space, building up a proton gradient.  This proton gradient 
makes up mitochondrial membrane potential and is the proton motive force that drives 
ATP synthesis by complex V.  Proton leak can be induced by uncoupling proteins (UCP) 
which dissipate the proton gradient, lowering mitochondrial membrane potential and 
increasing mitochondrial respiration uncoupled from ATP synthesis. 








































1.3 UNCOUPLING PROTEINS AND BODY WEIGHT 
Uncoupling proteins (UCPs) are nuclear encoded, transmembrane proteins that localize to 
the inner mitochondrial membrane and are thought regulate energy expenditure and body 
temperature by influencing the mitochondrial proton gradient. Within the larger family of 
mitochondrial solute carrier proteins (SLC25a) there are 5 proteins that make up the 
uncoupling protein family (UCP1-5)15. Uncoupling Protein 1 (UCP1) is considered the 
prototypical UCP as it was discovered first and is considered the only UCP to function as 
a protonophore (Table 1).  UCP1 is expressed in brown adipocytes and in a recently 
discovered population of white adipocytes which have a thermogenic capacity (beige or 
brown adipocytes)16,17.  UCP1 expression is crucial for mammalian temperature 
regulation by brown adipose tissue (BAT) and its expression is required for maximal fat 
oxidation in BAT during times of thermogenic stress. In this way, UCP1 regulates fat 
storage with relationship to environmental temperatures and limits fat accumulation in 
animals housed at temperatures below thermoneutrality (30°C)18.   
The relationship between UCP1 and energy expenditure in BAT and beige 
adipocytes has led many researchers to focus on UCP1 as a therapeutic target for obesity, 
however studies in humans have shown that BAT mass is inversely proportional to body 
weight, and beige adipocytes are present in very low numbers, effectively limiting the 
potential increase in energy expenditure that can be achieved by targeting endogenous 
UCP1 in obese individuals16,17,19.  
After the discovery of UCP1, two novel uncoupling proteins were discovered 
(UCP2 and UCP3) which led to great interest in the function of these homologs and their 
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relationship to thermogenesis and whole body metabolism20,21. UCP2 is expressed in 
many tissues including pancreas, lung, spleen, white adipose tissue and liver while UCP3 
expression is confined to skeletal muscle, BAT, heart and skin22-25.  Although much effort 
was extended to demonstrate that UCP2 and UCP3 could transport protons like UCP1, 
this does not seem to be the actual function of these novel UCPs and currently they are 
hypothesized to transport metabolites involved in TCA cycle function26,27.   
Despite the exact molecular function for UCP2 and UCP3 not being known, a 
clear link has been established between UCP2/3 function and whole body metabolism in 
humans through mutational and single nucleotide polymorphism (SNP) analysis28-34. 
UCP2 and UCP3 genes lie within 7kb of one another on chromosome 11 and that 
genomic region has been suggested to be a quantitative trait loci for body weight in 
humans35.  Although UCP2 does play a role in regulating systemic metabolism through 
regulation of insulin secretion in pancreas along with other tissue specific effects26,36, the 
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Table 1: Uncoupling protein expression and functions 
Tissue specific expression of uncoupling proteins likely reflect specialized functions in 
transport and regulating mitochondrial function. Direct proton transport is fundamental to 
thermogenesis and has only been observed with UCP1 in thermogenic tissues.  There is 
good evidence that UCP2 controls aspartate transport into the mitochondrial matrix 
resulting in reduced TCA cycle flux which can alter cellular response such as insulin 
secretion in pancreatic tissues26.  UCP3 is alternatively expressed in tissues which 
undergo lipid oxidation and is thought to support increased TCA cycle flux by importing 
malate.
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The finding that UCP3 is expressed in BAT and skeletal muscle led to initial 
hypotheses that this protein could be involved in thermogenesis and whole body 
metabolism however Ucp3 knockout mice display no basal metabolic phenotype37.  In 
response to cold exposure, Ucp3 ablation has no effect on core body temperature 
suggesting that it is not essential for cold-induced thermogenesis since compensatory 
mechanisms are likely to occur38.  Similarly, Ucp3 knockout mice are not obese but some 
evidence still points towards UCP3 regulation of systemic metabolism although the 
complete mechanisms are not well understood. A comprehensive study of whole body 
metabolism in UCP3 heterozygous (Ucp3+/-) and homozygous (Ucp3-/-) knockout mice 
with Ucp3+/+ mice as control demonstrated no difference in body weight among the three 
genotypes however both Ucp3-/+ and Ucp3-/- mice have increased fasting blood glucose 
and insulin levels compared with  Ucp3+/+ mice39.  When mice were fed a high fat diet for 
5 weeks, blood glucose levels were no longer increased but Ucp3-/- mice displayed 
significantly increased serum free fatty acid and insulin levels39.  These data indicate that 
UCP3 levels influence glucose homeostasis through a mechanism that is influenced by 
dietary fat intake.  In support of this, studies of long term high fat feeding (4-8 months) in 
Ucp3-/-, wild type and UCP3 skeletal muscle specific transgenic mice (UCP3-tg) have 
reported Ucp3-/- mice accumulate more body fat than wild type animals while UCP3-tg 
mice have reduced body fat compared with wild type40.  Additionally, UCP3-tg mice 
have reduced body weights; displays reduced fasting glucose and insulin levels, and are 
resistant to obesity and insulin resistance with high fat feeding40,41.  This data clearly 
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indicates a relationship between UCP3 expression and regulation of glucose-insulin 
homeostasis and adiposity. 
Most of what is known about UCP3 function has been determined from studies in 
skeletal muscle where UCP3 is induced in response to myoblast differentiation, thyroid 
hormone and cold exposure as well as fasting and high fat feeding42,43.  Although there is 
no evidence that UCP3 directly transports protons in skeletal muscle, mitochondria from 
Ucp3-/- mice have lower levels of uncoupled respiration and fat oxidation compared with 
wild type mice, suggesting that UCP3 may function similarly to how UCP1 directs fat 
oxidation in BAT38. Additionally, UCP3 function in skeletal muscle is similar to UCP1 in 
BAT in its ability to lower reactive oxygen species generation and mitochondrial 
membrane potential39,44-46.  Finally, both homologs are activated by free fatty acids and 
inhibited by purine nucleotides indicating that there are conserved aspects of UCP1 and 
UCP3 function despite the lack of proton transport by UCP327.   
Consistent with this, mice overexpressing UCP1 in white adipose tissue (WAT) or 
skeletal muscle are protected from diet-induced obesity suggesting a common mechanism 
shared by UCP3 and UCP18,47,48.  These studies indicate that uncoupling proteins increase 
the energy expenditure of the tissue in which they are overexpressed and therefore it is 
somewhat unsurprising that alterations to primary metabolic tissues by uncoupled 
respiration would influence whole body metabolism.  UCP3 expression in skin however 
has not been evaluated in this capacity and the focus of our studies was to determine if 
overexpression of UCP3 outside of primary metabolic tissues could have similar 
protective effects towards body weight and systemic metabolism.  
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1.4 SKIN BIOLOGY AND METABOLISM 
Skin is a large organ that prevents water loss and provides essential protection from the 
external environment. Whole skin is divided primarily into 2 layers: the dermis or lower 
layer contains sebaceous glands, vasculature, immune cells and substantial extracellular 
matrix material like collagen for structure and support, and the upper layer or epidermis 
contains mostly keratinocytes that undergo extensive differentiation to form a stratified 
epithelial layer and the epidermal lipid barrier.  The discussion below will focus primarily 
on the epidermal layer and metabolic profiles of keratinocytes which function 
reciprocally with systemic whole body metabolism.   
The epidermis is separated from the dermis by a basement layer made up of basal 
keratinocytes with tight junctions between cells.  These cells are generally proliferative 
and serve as a source for new cells to replace terminally differentiated anucleated 
corneocytes which are sluffed away. Keratinocytes undergo differentiation which consists 
of extensive protein synthesis for formation of keratin fibers and lipid synthesis for 
formation of lamellar bodies, which are secreted by the granular layer to form the 
epidermal lipid barrier. Basal cells undergoing differentiation will move up from the 
stratum basal into the stratum spinosum where proper synthesis of lamellar bodies and 
keratin fibers is essential for healthy skin.  From there, cells migrate up in the tissue and 
enter the granular layer (stratum granulosum) where keratohyalin granuals appear, cells 
dehydrate and lose their nuclei and organelles and secrete lamellar bodies. Finally, cells 
migrate into the cornified layer containing dead cells, surrounded by a cornified envelop 
with extensive lipid networks filling the extracellular space. This process of keratinocyte 
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proliferation and differentiation is regulated by an endogenous calcium gradient in vivo 
which can be mimicked in cell culture to induce differentiation49,50.  
The basal epidermis contains the most metabolically active cells in skin and since 
differentiation leads to loss of mitochondria, these cells are primarily responsible for 
mitochondrial oxygen consumption by epidermis.  That being said, the overall respiration 
rate is low in whole epidermis compared with other tissues, as differentiated 
keratinocytes primarily utilize glycolysis for ATP production51,52.  Previous studies have 
reported a respiratory quotient in epidermis close to 0.7 which should indicate that fatty 
acids are a predominant source of energy for mitochondrial ATP production51. This 
finding is curious since the majority of metabolic activity in skin is devoted to lipid 
synthesis, and a high rate of lipid oxidation would likely be futile toward overall tissue 
homeostasis.  
Epidermis represents a major site of de novo lipid synthesis that rivals rates of 
lipid synthesis in both liver and adipose tissue when compared by tissue mass53.  
Lipogenesis is a critical component of skin function and disruption of the epidermal lipid 
barrier can lead to trans-epidermal water loss and dehydration49. Barrier disruption also 
leads to an increase in cell differentiation and proliferation suggesting that keratinocytes 
respond to changes in epidermal lipid levels54. Lipid synthesis in epidermis utilizes 
circulating glucose as a carbon source and is stimulated in response to glucose ingestion 
and inhibited during starvation55.  During active epidermal lipid synthesis, glucose is 
taken up and oxidized to acetyl CoA and incorporated into the citrate pool in the 
mitochondria. Citrate is then exported by mitochondria and converted to cytoplasmic 
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acetyl CoA that is used as the primary source of carbon to make lipids, similar to lipid 
synthesis in liver and adipose tissue56.  Efficient lipogenesis therefore requires glucose 
and functional mitochondrial enzymes which indicates that basal keratinocytes represent 
the primary site of de novo lipid synthesis. 
Many early studies have indicated nutrition state can regulate epidermal lipid 
synthesis however, recently it was demonstrated that epidermis may have a reciprocal 
effect on systemic glucose metabolism. Mice lacking the fatty acid synthesis enzyme 
steroyl CoA desaturase 1 (SCD1) specifically in basal epidermis have improved glucose 
tolerance and resistance to high fat diet induced obesity57.  SCD1 catalyzes the rate 
limiting step in the synthesis of unsaturated fatty acids by converting palmitate and 
stearate into palmitoleate and oleate respectively58. Decreased enzyme expression leads to  
a marked reduction in sebaceous gland lipids and alterations to skin surface lipids59.  This 
finding demonstrates the capacity for alterations in epidermal lipid synthesis to affect 
systemic glucose metabolism and led to the hypothesis that increased lipid oxidation 





Illustration 4. Cell layers in epidermis 
Skin is separated in to dermal (lower) and epidermal (upper) which make up a stratified 
epithelial barrier from the external environment.  The epidermis is regenerated by cells in 
stratum basal which contains proliferative keratinocytes that can self-renew or undergo 
differentiation.  Upon differentiation, cells migrate into the stratum spinosum and 
generate keratin filaments and lamellar bodies.  From there, cells migrate in to the 
stratum granulosum and begin to flatten out as keratohyalin granuals appear.  As cells 
mover from the granular layer into the stratum corneum, lamellar bodies are released and 
lipids fill in the extracellular space surrounding terminally differentiated corneocytes.  
This lipid makes up the epidermal lipid barrier to protect against water evaporation from 
skin. Eventually corneocytes are sloughed off and replaced with cells migrating from 
lower layers of epidermis.  Keratinocyte differentiation is regulated by an in vivo calcium 









Chapter 2: Uncoupled respiration in skin promotes obesity resistance 
2.1 THE K5-UCP3 MOUSE MODEL AND METABOLIC PHENOTYPE 
In order to investigate the effects of UCP3 overexpression in basal epidermis, we 
utilized a mouse model in which murine Ucp3 expression is driven by the bovine keratin 
5 promoter (K5-UCP3).  This targets overexpression to basal epidermis and the basal 
layer of other stratified epithelial tissues.  Consistent with previous reports of Keratin 5 
promoter activity, we observed transgene expression in other stratified epithelial tissues 
including, oral cavity, esophagus, forestomach, pancreas, lung, bladder and bile duct60-62.  
Although use of this promoter is commonly used in genetic models for studies in basal 
epidermis, the bovine keratin 5 promoter has also been used to study carcinogenesis in 
bladder, pancreas, and gall bladder63-65. Our lab has previously demonstrated the degree of 
UCP3 overexpression in K5-UCP3 basal epidermis, as well as the correct localization of 
UCP3 protein to mitochondria in basal keratinocytes25. Additionally, previous studies 
confirmed transgene function through increased epidermal respiration and have shown 
that the increased respiration is solely due to increased lipid oxidation (Figure 1A).  
Gross phenotypic observations of K5-UCP3 mice included that pups were smaller than 
wild type littermates and the loss of hair, both phenotypes which seem to become less 
prominent as the mice age (Figure 1B).   
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Figure 1. Epidermal respiration due to fatty acid oxidation 
(a) Ex vivo epidermal respiration due to fatty acids. Whole epidermis was placed in a 
clark type electrode and oxygen consumption rate was assessed in the presence and 
absence of Etomoxir (Eto : 40µM) an inhibitor of CPT1 and mitochondrial fatty acid 
oxidation. Fatty acid dependent respiration was defined as the difference between total 
respiration and Eto inhibited (fatty acid independent) respiration.  Error bars represent 
mean ± SEM (WT FVB n=10, K5-UCP3 n=8). * Indicates significance from WT FVB/N 




































2.1.1 UCP3 overexpression in epidermis prevents obesity due to diet 
The small phenotype of K5-UCP3 mice was of particular interest to us and we set out to 
characterize the changes to systemic metabolism induced by uncoupled respiration in 
skin. Upon weaning (3-3.5 weeks old, male), transgenic mice weighed on average 20% 
less than wild type littermates and this reduction in body weight persisted through 6.5 
weeks accompanied by an increase in caloric consumption (Figure 2A-B).  To further 
understand the changes in body weight, we performed body composition analysis on 
young (6-9 weeks, male) and older (15 weeks, male) mice that indicated a significant 
reduction in both fat and lean mass in young mice with a reduction only in fat mass in 
older mice (Figure 2C).  The reduced fat mass in older mice suggests that as with 
overexpression in skeletal muscle67, epidermal UCP3 overexpression can limit fat 
accumulation.  This, taken with the knowledge that UCP3 overexpression drives 
increased lipid catabolism in skin led to the hypothesis that K5-UCP3 mice would be 
resistant to high fat diet-induced obesity. To test this, we weaned K5-UCP3 and wild type 
FVB/N littermates onto a control diet consisting of 10% kcal from fat (Research Diets, 
D12450) or a high fat diet consisting of 60% kcal from fat (Research Diets, D12492) and 
measured their body weight and caloric consumption for a period of 15 weeks.  The 
results of our high fat diet study were in agreement with our hypothesis and K5-UCP3 
mice were resistant to obesity due to high fat diet (Figure 2D-E). Although both 
genotypes gained a significant amount of body weight after consuming high fat diet, the 
K5-UCP3 mice maintained lowered body weights compared with wild type littermates 
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regardless of diet (Figure 2D-E).  There was no difference in the food consumption 
between genotype (Figure 2F), and body composition analysis revealed K5-UCP3 mice 
were resistant to fat accumulation seen in FVB/N littermates fed high fat diet. As well, 
we observed no difference in fat mass between K5-UCP3 mice fed a high fat diet with 
either genotype fed control diet (Figure 2G).  This data indicates that as seen in skeletal 
muscle40, UCP3 overexpression in epidermis can limit fat accumulation with obesogenic 
diet.  Collectively these data suggest UCP3 overexpression creates an imbalance in 
systemic metabolism to limit fat storage and we investigated regulation of glucose and 
lipid homeostasis to establish specific mechanisms by which phenotype had occurred.
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Figure 2.  UCP3 overexpression in epidermis reduces body weight and prevents obesity. 
(A) Body weight measurements, (B) caloric consumption, and (C) body composition 
analysis from FVB/N and K5-UCP3 littermates (male, 6 weeks old and 15 weeks old). * 
indicates significance from FVB/N (p< 0.05, ** p<0.01, ***p<0.001, ****p<0.0001). 
(D) Body weight measurements in FVB/N and K5-UCP3 male littermates fed control 
(CD) and high fat diet (HF) and (E) final body weights after 15 weeks.  (F) Caloric 
consumption measurements and (G) body composition analysis in FVB/N and K5-UCP3 
mice fed control or high fat diet.  Error bars are means ± SEM. * indicates significance of 
FVB/N HF compared with FVB/N CD. # indicates significance of K5-UCP3 HF 
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2.1.2 Uncoupled respiration in skin alters glucose homeostasis 
To gain an overall picture of epidermal metabolism in wild type and K5-UCP3 
littermates we performed metabolomic analysis on epidermis from 6-9 week old mice 
(gender matched, N=6) that had been fasted for 5 hours prior to tissue collection to 
control for feeding differences among mice. Among the multitude of changes to steady 
state metabolite levels observed between genotypes, markers of increased glucose and 
lipid catabolism were among the most abundant. (Figure 3A-C) UCP3 overexpression 
induced a reduction in 6 carbon intermediates at the beginning of the glycolytic pathway 
and builds up of end products pyruvate and lactate (Figure 3A).  We confirmed this 
increase in glycolysis by measuring increased lactate secretion in primary keratinocytes 
from wild type and K5-UCP3 epidermis indicating that UCP3 overexpression promotes 
aerobic glycolysis in a cell autonomous manner (Figure 3D).  Importantly, despite data 
indicating increased glycolysis and fatty acid oxidation in epidermis, primary 
keratinocytes from transgenic mice contained 20% less ATP than wild type cells 
indicating that UCP3 overexpression induced nutrient wasting in keratinocytes 
effectively increasing energy expenditure (Figure 3D). 
Consistent with previous studies of UCP3 overexpression in skeletal muscle39,67, 
we also observed a significant decrease in circulating blood glucose levels in both fasted 
and fed K5-UCP3 mice compared with wild type mice (Figure 4A). In addition we 
observed a modest decrease in fasting insulin levels suggesting that K5-UCP3 mice may 
be insulin sensitive (Figure 4B). 
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Figure 3.  Metabolomics Analysis and ATP levels in K5-UCP3 epidermis. 
Metabolomic analysis on 5 hour fasted FVB/N and K5-UCP3 epidermis using 
LC/MS/MS and GC/MS (Metabolon Inc.) values represent fold change from WT FVB/N 
for (A) Glycolysis (B) Free Fatty Acids and (C) Lysophospholipids66. (D) ATP levels and 
lactate secretion in isolated primary keratinocytes from FVB/N and K5-UCP3 mice. 
Values represent fold change from FVB/N. Error bars are means ± SEM. * Indicates 
significance from WT FVB/N p ≤ 0.
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To further investigate the relationship between increased glycolysis in epidermis 
and whole body metabolism we performed glucose (GTT) and insulin (ITT) tolerance 
tests on 6-9 week old wild type and transgenic littermates.  Briefly, this consisted of an 
overnight fast (14-16 hours) and a fasting blood glucose reading taken from the tail, 
followed by an intraperitoneal (I.P.) injection of glucose (2g/kg) or insulin (0.75U/kg) 
and regular blood glucose measurements over a period of 3 hours.  The GTT is a measure 
of overall glucose tolerance and the ability of the pancreas to respond to a standard 
glucose injection by secreting insulin to lower circulating glucose levels. Whereas, the 
ITT is a measure of the peripheral tissues to respond to a standard insulin injection and 
take up circulating glucose and inhibition of hepatic glucose production.  The results of 
these tests in K5-UCP3 mice indicated an increase in overall glucose tolerance as 
determined by a reduction in the area under the curve calculation (AUC) which was due 
to improved glucose clearance at 30 and 60 minutes post-injection (Figure 4C-D). Insulin 
sensitivity was not changed between the two genotypes however we did observe a modest 
reduction in fasting insulin levels in K5-UCP3 mice (Figure 4E, 4A).  This data suggests 
that reduction of blood glucose levels of transgenic mice may be due to an insulin-
independent mechanism and may result from increased basal glucose uptake by skin.  If 
basal glucose uptake is increased in the epidermis of K5-UCP3 mice it could consistently 
reduce blood glucose levels and reduce the amount of circulating insulin necessary to 
maintain glucose homeostasis.  
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Figure 4.  UCP3 overexpression in epidermis alters systemic glucose homeostasis. 
(A) Ad libitum fed and 14-16 hour fasting blood glucose levels and (B) fasting insulin 
levels in FVB/N and K5-UCP3 littermates.  (C) Glucose tolerance test with (D) AUC 
calculation, and (E) Insulin tolerance test with (F) AUC calculations. Error bars are 


























































































































We investigated the release of energy storage from adipose tissue upon fasting by 
measuring serum non-esterified fatty acid (NEFA) levels (Figure 5A). These data indicate 
no difference in serum NEFA between FVB/N and K5-UCP3 littermates suggesting that 
reduced fat mass did not alter release of energy stores from adipose tissue.  Reduced fat 
mass could lead to alteration in circulating hormones like leptin which can influence liver 
metabolism.  To investigate these questions, we examined metabolic gene expression in 
liver (which does not express UCP3) under fasted and fed conditions.  We observed no 
difference between genotypes in expression in phosphoenolpyruvate carboxykinase 
(PEPCK) which is involved in liver gluconeogenesis, pyruvate dehydrogenase kinase 4 
(PDK4) which regulates glucose oxidation in mitochondria or CPT1a which regulates 
fatty acid oxidation in liver (Figure 5B). This led us to conclude that alterations in liver 
function or circulating hormones were not a causal factor in hypoglycemia induced by 





Figure 5. UCP3 overexpression in epidermis does not alter adipose lipolysis or liver 
metabolism. 
(A) Fasting non-esterified fatty acid (NEFA) levels in wild type and K5-UCP3 plasma. 
(B) Liver mRNA levels of pyruvate dehydrogenase kinase 4 (PDK4), 
phosphoenolpyruvate carboxykinase (PEPCK) and carnitine palmitoyltransferase 1a 
(CPT1a) in wild type and K5-UCP3 mice ad lib fed and 14-16 hour fasted. Values 










































































2.1.3 Uncoupled respiration in skin blocks diet-induced metabolic dysfunction 
With the knowledge that UCP3 overexpression in skin drives fatty acid oxidation we 
hypothesized that epidermis might increase glucose uptake in an attempt to replenish 
lipid levels. Therefore we were interested if increased dietary fat content could rescue the 
glucose phenotype observed in transgenic mice.  Surprisingly, K5-UCP3 mice fed a high 
fat diet maintained reduced fasting blood glucose levels compared to wild type animals; 
however, 15 week old mice fed chow or control diet no longer displayed a reduction in 
fasting glucose which suggests glucose homeostasis in K5-UCP3 mice is altered as mice 
age (Figure 6A). We also observed significant changes in fasting insulin levels in K5-
UCP3 mice on both control and high fat diet (Figure 6B).  Despite this,  K5-UCP3 mice 
fed a control diet for 15 weeks showed no difference in glucose or insulin tolerance 
compared to wild type animals fed the same diet.  However, when mice were fed a high 
fat diet, epidermal UCP3 clearly prevents hyperglycemia, glucose intolerance and insulin 
resistance (Figure 6C-F).  Glucose tolerance tests in high fat fed animals indicated 
glucose intolerance in wild type mice that was not seen in transgenic mice as indicated by 
lowered AUC due to reduced fasting blood glucose levels, reduced peak circulating 
glucose 15 min after injection, and increased glucose clearance 1 hour post-injection 
(Figure 6C-D).  Insulin tolerance tests indicated insulin resistance in wild type animals 
fed high fat diet as measured by AUC calculations, however transgenic animals fed the 
same diet exhibited increased glucose clearance at 15 and 30 minutes post-injection 
(Figure 6E-F). Overall, this data provides a very interesting view of the capacity for 
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uncoupled respiration in epidermis to influence systemic metabolism and provides further 
evidence that targeting skin may be a therapeutic option for treating obesity and type 2 
diabetes.  
2.1.4 Mechanisms opposing obesity in K5-UCP3 mice 
The capacity for alterations in skin metabolism to influence systemic metabolism is a 
viable treatment option only if we understand the specific mechanisms that promote this 
effect.  The experiments presented thus far suggest a model where epidermal UCP3 
overexpression induces nutrient wasting, increasing basal glucose uptake in skin which 
reduces circulating glucose levels and limits fat accumulation.  Multiple pieces of data 
support the finding that UCP3 overexpression induced nutrient wasting in K5-UCP3 mice 
including: (1) Increased caloric consumption and decreased body weight in young 
animals (Figure 2A-B) (2) metabolomic analysis indicating global increase in nutrient 
oxidation of lipids and carbohydrates in transgenic epidermis (Figure 3A-C), (3) tissue 
respiration rates reveal increased uncoupled respiration and increased mitochondrial fat 
oxidation in K5-UCP3 epidermis (Figure 1A), and (5) increased lactate secretion but 
reduced ATP levels in primary keratinocytes from transgenic mice (Figure 3D).   
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Figure 6. UCP3 overexpression in epidermis prevents diet-induced hyperglycemia and 
insulin resistance. 
 
(A) Fasting blood glucose levels and (B) fasting insulin levels in 18 week old FVB/N and 
K5-UCP3 littermates fed control and high fat diet.  (C) Glucose tolerance test with (D) 
AUC calculation, and (E) Insulin tolerance test with (F) AUC calculations. Error bars are 
means ± SEM. * indicates significance between FVB/N HF compared with FVB/N CD 
(p< 0.05, ** p<0.01, ***p<0.001, ****p<0.0001) # indicates significance of K5-UCP3 
HF compared with FVB/N HF
 33 
To confirm that basal glucose uptake is enhanced in K5-UCP3 mice we measured 
expression of glucose transport proteins in wild type and transgenic epidermis (Figure 
7A).  Previous studies have demonstrated that keratinocytes express glut1, 2, 3, and 5 
which are differentially regulated in response to differentiation as well as insulin and 
IGF-168. Calcium induced keratinocyte differentiation specifically upregulates expression 
of Glut3, which has higher efficiency than other transporters and higher affinity towards 
glucose, and downregulates expression of glut1, 2, and 5. Additionally, insulin 
stimulation increases translocation of Glut 1 and 5 while IGF stimulation induces 
translocation of Glut 2 and 3 although neither stimulation results in increased glucose 
uptake by keratinocytes demonstrating that Glut translocation in epidermis is not 
involved in insulin-stimulated glucose clearance68.  Consistent with our hypothesis that 
UCP3 overexpression increases basal glucose uptake in epidermis, we observed induction 
of glut 1 and glut 3 mRNA in K5-UCP3 epidermis compared with FVB/N littermates in 
both the fasted and fed state and confirmed these results in fed mice by western blot 
analysis (Figure 7B).  The induction of glut 3 mRNA was not significant and protein 
levels were only slightly increased suggesting its increase may be associated with  
increased differentiation markers observed in transgenic epidermis.  Importantly, there 
was no change in glut1 or glut3 transcripts with fasting versus feeding in either genotype 
suggesting that transporter expression is not related to physiological changes in nutrient 
availability (Figure 7A).  In support of our hypothesis that increased glucose uptake in 
skin is a mechanism that opposes obesity, Glut1 protein remained increased in K5-UCP3 
epidermis with both control and high fat diet compared to FVB/N littermates (Figure 7C), 
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whereas Glut 3 protein was not altered by genotype or diet (data not shown).   This data 
suggests that increased Glut1 expression in epidermis is critical to the mechanism 
opposing hyperglycemia due to diet in K5-UCP3 mice. 
We sought to understand the molecular mechanisms leading to increased glucose 
transporter expression in epidermis and focused on the role of AMP-activated kinase 
(AMPK) activation due to its established relationship with both uncoupling and glucose 
transporter regulation in skeletal muscle.  Western blot analysis indicated activation of 
AMPK in transgenic epidermis as indicated by phosphorylation of threonine 172 (T172) 
along with phosphorylation and inhibition of its downstream target, ACC at serine 79 
(S79) (Figure 7B). AMPK activation and ACC inhibition was maintained in the 
epidermis of transgenic mice fed both control and high fat diet allowing us to conclude 
that AMPK activation and ACC inhibition are key factors contributing to mechanism by 
which UCP3 overexpression in epidermis attenuates fat accumulation and obesity (Figure 
7C).  Increased AMPK activation and ACC phosphorylation indicates inhibition of 
epidermal de novo lipid synthesis69 and simultaneously provides a mechanism for 
increased fatty acid oxidation in K5-UCP3 epidermis through reduced cytoplasmic 
malonyl CoA levels.  Inhibition of ACC and lipid synthesis may mimic some changes to 
systemic metabolism seen in skin specific SCD1-/- mice suggesting that blocking lipid 
synthesis in epidermis is sufficient to lower circulating glucose levels70.  The effect of 
skin SCD1 knockout on glucose metabolism is rescued by high fat feeding however 
which indicates UCP3 overexpression promotes changes to glucose metabolism through 
an alternative mechanism, likely AMPK activation and increased glucose transporter 
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expression. Future studies distinguishing the effects of AMPK activation and inhibition 
of lipid synthesis on glucose transporter expression in epidermis would provide critical 
details necessary for targeting this pathway to limit the development of insulin resistance 
and type 2 diabetes.  
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Figure 7. Mechanisms opposing obesity in epidermis of K5-UCP3 mice. 
 
(A) mRNA levels for glut1 and glut3 normalized to B2M control gene in FVB/N and K5-
UCP3 fasted (14-16 hours) and fed epidermis. (B) Immunoblot for glucose transporters 
(glut1 and glut 3) and AMPK activation by phosphorylation at T172 and downstream 
inhibition of ACC by phosphorylation at S79. Samples are 4 independent epidermal 
samples from 6-9 week old ad lib fed mice.  (C) Immunoblotting in FVB/N and K5-
UCP3 mice fed control or high fat diet for 15 weeks.  Samples are 3 independent 

















































Chapter 3: Uncoupled respiration in epidermis inhibits tumorigenesis 
3.1 METABOLISM AND CANCER 
Within the last several decades our understanding of metabolism has been greatly 
expanded through studies of metabolism in cancer.  Cell growth and proliferation are 
energetically demanding processes that require effective metabolism of available 
nutrients along with proper regulation of gene expression and signaling.  Oncogenic 
mutations in metabolic enzymes, signaling proteins and transcription factors can all 
promote a metabolic switch that supports the high proliferative demands of cancer cells 
thus interventions that obstruct this metabolic switch can theoretically prevent cancers in 
many tissues and with varied genotypes71. Metabolic reprogramming seen in cancers is 
largely defined as the increase in aerobic glycolysis and reduced mitochondrial substrate 
oxidation defined as the Warburg effect.  Glycolysis is much less efficient for ATP 
production compared to oxidative phosphorylation in mitochondria however this switch 
allows proliferating cells to generate considerable amounts of biomass in the form of 
nucleotides, amino acids and intermediates for lipid synthesis from glycolytic 
intermediates71.  Decreased oxidative phosphorylation in mitochondria also increases the 
capacity for cells to liberate TCA cycle intermediates like citrate to support de novo lipid 
synthesis which is critical for cancer cell growth since blocking this process can limit  
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proliferation both in vitr1o and in vivo72,73.  With this knowledge, we hypothesized that 
uncoupled respiration could limit both the energy and metabolic intermediates required 
for biosynthesis in cancer cells effectively limiting their proliferative potential. 
3.1.1 UNCOUPLED RESPIRATION REDUCES PROLIFERATION IN RESPONSE TO TPA 
Initial studies using K5-UCP3 mice tested the hypothesis that uncoupled 
respiration is incompatible with cancer cell growth25.  To address this question in vivo, we 
employed the two stage chemical carcinogenesis model, which mimics multi-stage skin 
carcinogenesis seen in humans74.  Briefly, mice were exposed to an initial 
subcarcinogenic dose of the DNA damaging agent 7,12-Dimethylbenz[a]anthracene 
(DMBA) followed by a two week washout period and then biweekly treatment with the 
tumor promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA).  This method 
induced papilloma formation in wild type animals after 5 weeks of TPA treatment 
however K5-UCP3 mice showed a 10 week latency in papilloma formation and greatly 
reduced papilloma multiplicity.  Similarly, wild type animals showed papilloma 
progression to carcinomas after 10-12 weeks of TPA treatment while K5-UCP3 mice 
were completely resistant to carcinoma formation25. To further investigate the 
mechanisms by which UCP3 overexpression prevents tumorigenesis, we crossed K5-
                                                
1  Portions of this chapter are adapted from:   
Sara M. Nowinski*, Ashley Solmonson*, Joyce E. Rundhaug, Okkyung Rho, Christine K. Dao, 
Cory U. Lago , Kaoru Kiguchi, Susan M. Fischer, John Digiovanni, and Edward M. Mills. 
Mitochondrial uncoupling links lipid catabolism to inhibition of Akt and cancer 
resistance. Nature Communications  6:8137.  August 2015. * These authors contributed 
equally to this work. 
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UCP3 mice with “pre-initiated” mice harboring an oncogenic v-Ha-RAS transgene 
(Tg.AC mice) in an attempts to distinguish between UCP3-induced effects on tumor 
initiation and tumor promotion75.  In this second tumor study, Tg.AC mice and K5-
UCP3/Tg.AC mice received 4 treatments of TPA which induced papilloma formation in 
Tg.AC mice within a 1-2 weeks after TPA treatment however K5-UCP3/Tg.AC showed a 
15 week latency in papilloma incidence with significantly reduced papilloma multiplicity 
(Figure 8A-C).  In addition, similar to the initial tumor study, K5-UCP3/Tg.AC mice 
were completely resistant to carcinoma formation supporting the hypothesis that UCP3 
overexpression blocks skin carcinogenesis (Figure 8D-E). The results of this second 
study indicate that UCP3 overexpression primarily blocks the tumor promotion stage of 
skin carcinogenesis and further experiments focused on the effects of UCP3 
overexpression on keratinocyte proliferation in response to TPA treatment. 
We began by measuring DNA synthesis in vivo by labeling proliferative cells with 
5-bromo-2-deoxyuridine (BrdU) after topical treatment of either vehicle (acetone), single  
TPA treatment (1x) and multiple TPA treatments (4x) (Figure 8F).  Although K5-UCP3 
epidermis did display a modest increase in basal keratinocyte proliferation compared to 
wild type with vehicle treatment, the proliferative response to TPA treatment was 
severely blunted with just a 1.5 fold increase in proliferation compare with the 7 fold 
increase seen in wild type epidermis (Figure 8G). Taken with our data of increased 
differentiation in K5-UCP3 epidermis this data suggests a small increase in basal cell 
proliferation may compensate for increased keratinocyte turnover in transgenic epidermis 
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however stimulated proliferation is markedly decreased in response to UCP3 
overexpression.  
3.3.2 UNCOUPLED RESPIRATION BLOCKS AKT ACTIVATION 
To understand the mechanisms responsible for inhibiting proliferation in 
transgenic epidermis, we investigated signaling events downstream of TPA treatment. 
K5-UCP3 epidermis also failed to induce cell cycle proteins cyclin A and cyclin D, and 
maintained expression of cell cycle inhibitory proteins p21 and p27 in response to TPA 
(Figure 9A).  Broad analysis of cell signaling pathways indicated a striking reduction in 
activation of Akt (protein kinase B) as observed by decreased phosphorylation at both 
serine 473 (S473) and threonine 308 (T308) (Figure 9B). This corresponded to reductions 
in phosphorylation of downstream targets of Akt including glycogen synthase kinase-3β 
(GSK3β-S9), Forkhead box protein O1 (FOXO1 S256, S319)  (Figure 9B). 
Akt is a serine/threonine protein kinase that is activated in response to mitogens 
including epidermal growth factor (EGF) through a mechanism that requires membrane 
localization of Akt and phosphorylation by mammalian target of Rapamycin complex 2 
(mTORC2) at S473 and Phosphoinositide-dependent kinase 1 (PDK1) at T308.  Active 
Akt has a relatively broad impact on cellular function by phosphorylating proteins 
involved in cell cycle progression, cell survival/anti-apoptosis, protein translation, and 
cellular metabolism.  Specifically with regard to cellular metabolism, activation of Akt 
leads to increased glycolysis, increased lactate production and increased lipogenesis 
however little is known about if changes cellular metabolism can influence Akt activity.  
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Figure 8. UCP3 blocks tumor promotion 
(A) Timeline of Tg.AC tumor study. 16 week-old mice were shaved dorsally and treated 
topically with TPA biweekly for 2 weeks for a total of 4 treatmets. (B) Tumor 
development in “pre-initiated” Tg.AC and bigenic K5-UCP3/Tg.AC mice indicating total 
papillomas/mouse, (C) % mice bearing papillomas, (D) total carcinomas/mouse, and (E) 
% mice bearing carcinomas. (E) Immunohistochemistry for BrdU labeled cells in wild 
type FVB and K5-UCP3 epidermis following topical treatment with Acetone (vehicle 















































































































microns.  (F) Quantification of percentage of BrdU-positive labeled cells in the basal 
layer of the interfollicular epidermis (IFE). Error bars are means +/- SEM.  * indicates 
significantly different from Acetone control, same genotype (** p<0.01, *** p<0.0001), 
† indicates significantly different from wild type FVB, same treatment (††† p<0.0001). 
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Furthermore,  Akt is central to the phosphatidylinositol 3-kinase (PI3K) – Akt – mTOR 
signaling pathway which is frequently hyperactive in cancer cells with mutations 
frequently found in PI3K, PTEN, Akt, TSC2, and mTOR, highlighting the importance of 
identifying novel mechanisms to inhibit this pathway. Our finding that overexpression of 
UCP3 inhibits Akt activation was suggestive of a novel mechanism through which 
targeting metabolism can inhibit proliferation thus we set out to determine the 
mechanisms by which this inhibition had occurred.   
In our analysis of signaling events downstream of Akt, we observed 
phosphorylation of mTOR at S2448 that was either unchanged of slightly diminished and 
auto-phosphorylation at S2481 was unaffected. These indicate a maintenance of mTOR 
activity in TPA-treated K5-UCP3 epidermis despite reduced Akt activation and AMPK 
activation.  This is supported by no difference between transgenic and wild type TPA-
treated epidermis in phosphorylation of targets downstream of mTORC2, ribosomal S6, 
(rS6), eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) and 
eukaryotic factor 4G (eIF4G) (Figure 9C).  This data, along with activation of AMPK in 
epidermis suggests that the PI3K-Akt-mTOR pathway may undergo unique metabolic 
regulation in keratinocytes and certainly warrants further investigation. 
To identify if the mechanisms leading to Akt inhibition were cell autonomous, we 
isolated primary keratinocytes from wild type and transgenic mice and treated these cells 
with EGF or vehicle (BSA) for 30 minutes (Figure 9D).  Akt activation was robust in 
wild type cells however K5-UCP3 keratinocytes maintained reduced Akt activation 
indicating that the mechanism was indeed cell autonomous and was not specific to TPA 
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stimulation as EGF also failed to activate Akt. With the knowledge that EGF stimulation 
failed to activate Akt in primary cells, we investigated the activation of the EGF receptor 
(EGFR) in K5-UCP3 primary cells by immunoblot for tyrosine 1086 (Y1086) (Figure 
9E). EGFR activation was unaffected by UCP3 overexpression leading us to conclude 
that blockade of Akt activation occurred downstream of EGFR.  Additionally, we 
demonstrated UCP3-induced inhibition of Akt in human primary neonatal keratinocytes 
transfected with UCP3, indicating that this mechanism is not specific to murine cells 
(Figure 9F).   
Our data indicated reduced phosphorylation of both S473 and T308 thus we 
examined the activity of protein phosphatase 2A (PP2A) which is responsible for 
dephosphorylating both sites to inactivate Akt.  The expression of PP2A subunits was not 
altered by UCP3 overexpression (data not shown), however results of an in vitro 
phosphatase assay indicated that basal PP2A activity was increased in K5-UCP3 
epidermis (Figure 9G).   This data was in line with decreased activation of another PP2A 
target, p38-MAPK in transgenic epidermis after TPA treatment however when mice were 
treated topically with the PP2A inhibitor okadaic acid,  p38-MAPK activation was 
rescued completely whereas Akt activation was only partially rescued (Figure 9H).  From 
this data we concluded that although PP2A hyperactivity played a role in reduced Akt 
activation in K5-UCP3 epidermis, there was likely an additional mechanism by which 
UCP3 overexpression could inhibit Akt.  
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3.3.3 INCREASED β-OXIDATION BLOCKS AKT MEMBRANE RECRUITMENT IN 
KERATINOCYTES 
Downstream of EGFR activation, EGF stimulation activates PI3K to 
phosphorylate phosphatidylinositol 4,5-bisphosphate (PIP2) to generate 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in cellular membranes.  The 
accumulation of PIP3 provides a docking site for the pleckstrin homology domain (PH 
domain) of Akt resulting in membrane recruitment and activation of Akt through 
phosphorylation by upstream kinases mTORC2 and PDK176.  We investigated whether 
UCP3 overexpression affected Akt membrane recruitment in epidermal membranes of 
acetone and TPA treated mice.  Immunoblot for total Akt showed reduced Akt levels in 
membrane fractions taken from K5-UCP3 mice after TPA treatment compared to wild 
type littermates indicating that UCP3 overexpression blocks Akt membrane recruitment 
(Figure 10A-B).  The data presented thus far suggest a model where UCP3 
overexpression blocks tumor promotion through reduced proliferation resulting from 
inhibition of Akt membrane recruitment.  The localization of UCP3 to the inner 
mitochondrial membrane suggests an indirect mechanism inhibiting Akt membrane 
recruitment and thus we focused on our knowledge of UCP3 functional effects on cellular 
metabolism.  Initially, we hypothesized that UCP3 overexpression may decrease cellular 
reactive oxygen species (ROS) generation which might explain PP2A hyperactivity as 
well as Akt inhibition.  However we were unable to detect any difference in overall 
cellular ROS or ROS generated by isolated mitochondria from K5-UCP3 epidermis (data 
not shown).  As well, we observed no difference in the redox state of PP2A or Akt (data 
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not shown) leading us to conclude that UCP3 mediated reduction in ROS was not the 
mechanism by which Akt inhibition had occurred . Subsequently, we investigated the role 
of UCP3 induced lipid catabolism as a mechanism to inhibit Akt activation with the use 
of epidermal metabolomics.  Analysis of steady state metabolite levels in K5-UCP3 
epidermis indicated global reduction in free fatty acids and acyl-carnitines indicating 
increased lipid catabolism as a result of uncoupled respiration (Figure 3B).  Additionally, 
uncoupled respiration increased the levels of lysophospholipids indicating increased 
phospholipid breakdown in K5-UCP3 epidermis and suggesting possible altered 
membrane composition (Figure 3C). Using this information, we hypothesized that 
increased lipid catabolism in K5-UCP3 epidermis altered membrane dynamics and 
reduced the activation potential of Akt at the membrane.
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Figure 9. UCP3 overexpression inhibits Akt activation 
(A) Immunoblot for Akt phosphorylation at Ser 473, along with total Akt, Cyclin D1 
Cyclin A, p21 (Cip1/Waf1) and p27 (Kip1) expression following treatment with Acetone 
(vehicle control, 4 hours post-treatment) or TPA (4 hours & 18 hours post-treatment) in 
wild type FVB and K5-UCP3 epidermal lysates. (B) Immunoblot for Akt 
phosphorylation at Ser 473 and Thr 308, and Akt targets, FOXO1 at Ser 256 and Ser 319, 
and GSK3β at Ser 9 in wild type FVB and K5-UCP3 epidermal lysates, following 
treatment with TPA or Acetone.  (C) Immunoblot for phosphorylation of mTORC1 
pathway members: TSC2 Ser 939, mTOR Ser 2448, Ser 2481, 4EBP1 Thr 36/47, rS6 Thr 
240/244, and eIF4G Ser 1108, in wild type FVB and K5-UCP3 epidermal lysates 
following topical treatment with 2.5 µg TPA or Acetone. (D) Immunoblot for 
phosphorylation of Akt Ser 473 in serum starved wild type FVB and K5-UCP3 primary 
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(vehicle control).  (E) Immunoblot for phosphorylation of epidermal growth factor 
receptor (EGFR, Ser 1086) in serum starved wild type FVB and K5-UCP3 primary 
epidermal keratinocytes 15 minutes after treatment with 40 ng/mL EGF or 0.001% BSA. 
(F) Immunoblot for phosphorylation of Akt Ser 473 in primary neonatal human 
keratinocytes transiently transfected with UCP3 or empty vector control (EV) and treated 
with 40 ng/mL EGF or 0.001% BSA.  Immunoblot for UCP3 confirmed successful 
transfection. (G) In vitro PP2A catalytic activity, expressed as fold change compared to 
wild type.  Immunoprecipitated PP2Ac was incubated with a target phosphopeptide and 
free phosphate release was measured using a malachite green assay and absorbance at 
620 nm.  Error bars are means +/- SEM. *** indicates significantly different from wild 
type (p<0.001). (H) Immunoblot for Akt Ser 473 and p38 MAPK T180/Y182 
phosphorylation in wild type FVB and K5-UCP3 epidermal lysates 1 hour following 
topical treatment with 5 nmol okadaic acid (OA) or acetone (vehicle control).  
Immunoblotting for β-Actin was used to confirm equal loading (A-F, H)
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To test this hypothesis, we treated wild type and K5-UCP3 mice topically with the 
CPT1 inhibitor, etomoxir to inhibit mitochondrial fatty acid import and oxidation.  
Surprisingly, etomoxir not only increased basal Akt activation in transgenic epidermis but 
also in wild type epidermis indicating that fatty acid oxidation is indeed a novel 
mechanism to regulate Akt activation (Figure 10C) 
3.3.4  OVEREXPRESSION OF AKT RESCUES PROLIFERATION IN K5-UCP3 EPIDERMIS 
To confirm that UCP3-mediated lipid oxidation was of functional importance in 
the tumor resistant phenotype of transgenic mice, we inter-bred K5-UCP3 animals with 
mice overexpressing a wild type Akt transgene also targeted to basal epidermis (K5-Akt) 
to generate bi-transgenic mice (K5-UCP3/K5-Akt) 77.  We used these mice to test 
whether increased expression of Akt could overcome the metabolic regulation of UCP3 
in epidermis and rescue cell proliferation and tumorigenesis. K5-Akt mice have been 
previously reported to have increased Akt expression and basal activation compared to 
wild type controls and we observed this effect in bi-transgenic mice as well indicating 
that Akt overexpression was sufficient to overcome inhibition by UCP3 (Figure 11A).  
Consistent with this, BrdU labeling in vivo indicated overexpression of Akt rescued cell 
proliferation in response to TPA treatment as well as tumorigenesis when subjected to the 
two-stage chemical carcinogenesis protocol (Figure 11B-C). 
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Figure 10. Mitochondrial β-oxidation alters plasma membrane lipids & signaling   
(A) Immunoblot for sub-cellular localization of Akt and PTEN in membrane and 
cytoplasmic fractions from wild type FVB and K5-UCP3 epidermis topically treated with 
2.5 µg TPA or Acetone. α-3 Integrin and β-Actin were used as controls to verify 
membrane and cytoplasmic fractions, respectively.  (B) Relative quantification of Akt in 
cytoplasmic and membrane fractions from triplicate separate immunoblotting 
experiments via densitometry.  Cytoplasmic and membrane fractions were normalized to 
β-Actin and α3-Integrin, respectively.  Error bars are means +/- SEM.  * indicates 
significantly different from wild type FVB, same treatment (* p<0.05). (C) Immunoblot 
for Akt Ser 473 phosphorylation in wild type FVB and K5-UCP3 epidermal lysates 6 
hours following topical treatment with 1 mg etomoxir ethyl ester (Eto) or ethyl acetate 
(EA, vehicle control).  Immunoblotting for β-Actin was used to confirm equal loading. 
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Figure 11. Overexpression of Akt rescues proliferation in K5-UCP3 epidermis 
 (A) Immunoblot for Akt phosphorylation at Ser 473 in wild type FVB, K5-UCP3, K5-
Akt, and bitransgenic K5-UCP3/K5-Akt epidermal lysates, 4 hours following topical 
treatment with 2.5 µg TPA or Acetone (vehicle control).  Immunoblotting for β-Actin 
was used to confirm equal loading. (B) Immunohistochemistry for BrdU labeled cells in 
wild type FVB/N, K5-UCP3, K5-Akt, and bitransgenic K5-UCP3/K5-Akt epidermis 
following topical treatment with single (1x) or multiple (4x) treatments with 2.5 µg TPA 
or Acetone.  Scale bars = 50 microns.  (C) Quantification of BrdU labeled cells in the 
basal layer of the interfollicular epidermis (IFE). >100 cells from 5 randomly selected 
skin sections (total >500 cells) were counted from each of n = 3 mice per genotype in 
each treatment group. Error bars are means +/- SEM.  * indicates significantly different 
from Acetone control, same genotype (** p<0.01, *** p<0.0001), † indicates 
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3.3.5  OVEREXPRESSION OF AKT RESCUES TUMORIGENESIS 
Both K5-Akt and K5-UCP3/K5-Akt mice formed more tumors than wild type 
mice with a modest latency in papilloma multiplicity observed in bi-transgenic animals 
compared to K5-Akt mice however both groups formed more tumors more rapidly and 
abundantly compared with wild type mice (Figure 12A-B).  Bi-transgenic mice were not 
resistant to carcinoma formation, developing more carcinomas more quickly than wild 
type mice however we did observe a reduction in carcinoma formation compared with 
K5-Akt mice (Figure 12C-D).  Collectively this data suggests that Akt inhibition is a 
critical component to the cancer resistant phenotype seen in K5-UCP3 mice however bi-
transgenic mice are still somewhat protected from tumorigenesis compared with K5-Akt 
mice suggesting that UCP3 may limit tumor progression even with Akt overexpression.  
Importantly, in this third tumor study no carcinomas were observed on any K5-UCP3 
animals providing very strong evidence that uncoupled respiration is incompatible with 
carcinogenesis (Figure 12 D).  
Through these studies we have demonstrated a novel mechanism by which lipid 
metabolism in keratinocytes regulates cell proliferation through Akt activation.  We have 
proven this mechanism to be cell autonomous and present in both mouse and human 




Figure 12. Overexpression of Akt rescues tumorigenesis 
(A) Tumor development in wild type FVB, K5-UCP3, K5-Akt, and bitransgenic K5-
UCP3/K5-Akt mice indicating total papillomas/mouse, (B) % mice bearing papillomas, 
(C) total carcinomas/mouse, and (D) % mice bearing carcinomas.
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Chapter 4: Final Thoughts 
The concepts described within describe two mechanisms that oppose obesity and 
skin cancer, two of the most common diseases in humans.  This data also links many 
concepts that have been well studied but not well connected by molecular mechanisms.  
Increasing energy expenditure has long been understood to be a mechanism to lower 
body weight and oppose obesity however the role of epidermis in this regard has not been 
well studied.  The role that endogenous uncoupling protein expression in the 
physiological regulation of body weight is not completely clear, which makes models like 
the K5-UCP3 mouse a valuable asset in obesity research.  It is important to note, we did 
observe UCP3 overexpression in other tissues in which keratin 5 is endogenously 
expressed, such as bladder, lung, forestomach, pancreas and esophagus. Although we 
chose to focus on epidermis as it relates to control of systemic metabolism, we cannot 
rule out effects of UCP3 overexpression in oral cavity, esophagus and forestomach 
specifically due to the exposure to dietary nutrients in contributing to the anti-obesity 
phenotype of K5-UCP3 mice.  We can use the data here to compare the functions of 
overexpression of UCP3 in epidermis to models where it is overexpressed in skeletal 
muscle to compare and contrast the roles that these two tissues play in regulating overall 
body weight. Furthermore, we can compare studies with ectopic expression of UCP1 in 
adipose tissue and skeletal muscle with the effects of UCP3 overexpression to understand 
what mechanisms are activated by uncoupling proteins in those tissues and how they may 
be targeted therapeutically.   
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Our data here demonstrate that UCP3 overexpression in epidermis increases 
glycolysis and fatty acid oxidation through upregulation of Glut1 and activation of 
AMPK.  This phenotype is very similar to the effects of overexpression of UCP3 or 
UPC1 in skeletal muscle which also improve glucose tolerance and oppose 
obesity44,47,67,78.  This suggests that both proteins may activate a similar mechanism to 
increase skeletal muscle energy expenditure.  Interestingly, if these studies are compared 
to ectopic expression of UCP1 in white adipocytes or in liver, a common mechanism 
activated by uncoupling that can induce effects on whole body metabolism.   Specifically, 
UCP1 overexpression in white fat, muscle or liver leads to reduced body weight after 
high fat diet, increased overall energy expenditure, reduced plasma insulin and increased 
glucose tolerance.  These phenotypes are similar to what is known about the role of 
AMPK activation in these tissue and the differences in phenotypes between the three 
models are similar to the effects of tissue specific AMPK activation8. 
The general function of active AMPK is to increase nutrient uptake and energy 
production and to inhibit processes that consume large amounts of ATP79. One example 
of how this occurs is through inhibition of acetyl CoA carboxylase (ACC) which converts 
cytoplasmic acetyl CoA to malonyl CoA in one of the first steps of de novo lipid 
synthesis80,81.  ACC inhibition also serves a function in increasing fatty acid oxidation 
since its product, malonyl CoA, acts as an endogenous inhibitor of carnitine palmitoyl 
transferase 1 (CPT1) in the carnitine shuttle for fatty acid oxidation69.  Fatty acids are 
imported into mitochondria using the carnitine shuttle and are oxidized in the matrix 
through β-oxidation enzymes, and normal physiological increases in cytoplasmic malonyl 
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CoA inhibit CPT1 from importing newly synthesized lipids into mitochondria for 
oxidation during activation of de novo lipid synthesis.  Thus, AMPK inhibition of ACC 
represents a major regulatory point in cellular lipid metabolism and phosphorylation 
states of both proteins can be used as an indicator for evaluating lipid synthesis and 
oxidation.  The effects of AMPK activation and ACC inhibition by UCP3 overexpression 
in epidermis have similar effects on systemic metabolism with skin–specific Scd1 
knockout mice. This suggests that inhibition of lipid synthesis in epidermis through Scd1 
knockout, AMPK activation or ACC inhibition may be sufficient to influence whole body 
metabolism. 
AMPK activation also promotes increased glucose uptake and glycolysis which is 
a quick and relatively effective mechanism to restore cellular ATP levels and energy 
homeostasis.  AMPK activation promotes translocation of GLUT proteins to the plasma 
membrane to increase glucose uptake and phosphorylates glycolytic enzymes to facilitate 
effective ATP synthesis from glycolysis. Contraction in skeletal muscle leads to AMPK 
activation both in vivo and ex vivo and multiple studies have demonstrated that this leads 
to increased GLUT4 translocation to the plasma membrane and increased glucose 
uptake82-85. Furthermore, this mechanism requires the AMPK upstream kinase, LKB1 
since glucose uptake is abolished when LKB1 is ablated specifically in skeletal muscle86.  
Interestingly, it has been suggested that long-chain fatty acid esters might inhibit AMPK 
activation suggesting a feed back mechanism to limit AMPK activation when fatty acids 
are increased87.  Thus AMPK activation is likely integral to the metabolic profile induced 
 57 
by UCP3 overexpression in epidermis and more needs to be investigated about epidermal 
AMPK activation as a potential target for treating obesity. 
The second mechanism discussed herein demonstrates novel metabolic regulation 
of Akt and keratinocyte proliferation. With UCP3 overexpression, increased lipid 
oxidation leads to phospholipid breakdown, reduced membrane recruitment, and reduced 
activation of Akt.  Keratinocytes will degrade phospholipids when grown in the absence 
of glucose which suggests that this mechanism may be specific to epidermis since other 
tissues may increase fatty acid uptake under energy limiting conditions88.  We 
investigated whether high fat diet might rescue UCP3-induced Akt inhibition however 
transgenic mice fed a high fat diet maintained Akt inhibition in epidermis (data not 
shown).  This suggests that inhibition of lipid synthesis or depletion of specific lipid 
species may be critical to recapitulating this mechanism to inhibit cancer growth. 
Many studies have demonstrated the presence of lipid rafts in cellular membranes 
that are critical for activation of signaling cascades that initiate with extracellular ligand 
binding transmembrane receptors like EGFR.  Specifically, Akt has been shown to co-
localize with detergent-resistant lipid rafts in keratinocyte membranes89 and two separate 
studies have indicated Akt is more effectively activated when located in lipid-raft 
regions90,91.  Disruption of membrane fluidity with cholesterol depleting agents results in 
rapid inactivation of Akt providing additional evidence that membrane composition 
requirements are essential for maximal Akt activation89.  These studies provide a 
framework for further investigation into how UCP3 overexpression inhibits Akt 
activation through increasing lipid oxidation in epidermis.  A deeper understanding of the 
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specific lipid oxidative pathways that degrade phospholipids in K5-UCP3 epidermis 
would provide an informed context for developing therapeutics to target this mechanism 
in skin cancers
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Chapter 5: Materials and Methods 
Reagents.  
 Glucose (50% dextrose/water) and insulin (Humulin R) were purchased from Animal 
Health International (Greeley, CO).  12-O-tetradecanoylphorbol-13-acetate  (TPA)  and  
okadaic  acid  (OA)  were  purchased  from  LC Laboratories  (Woburn, MA).   Etomoxir  
ethyl  ester  (Eto)  was purchased  from  US  Biological  (Salem, MA).  Acetone, 7,12-
dimethylbenz[a]anthracene (DMBA), and all other reagents (unless  
otherwise noted) were purchased from Sigma (St. Louis, MO) 
. 
Animals.  
K5-UCP3 (FVB/N) mice were generated as previously described 25 using a bovine keratin 
5 promoter and murine UCP3 construct and maintained as hemizygous breeder colonies 
with FVB/N mice purchased from Jackson Laboratories (Bar  Harbor, ME).  All 
experiments were performed in male littermates at either 6-9 weeks old or 15-18 weeks 
old (diet studies) housed under a 12-hour light-dark cycle with ad libitum access to food 
and water; in accordance with the guidelines defined by the Association for Assessment 
and Accreditation of Laboratory Animal Care (AAALAC) with approval from the 
Institutional Animal Research Committees at The University of Texas at Austin and UT-
MD Anderson Science Park Research Division.  Unless otherwise specified, mice were 
weaned at 3 weeks old onto Prolab RMH 1800 chow diet from LabDiet (St. Louis, MO).  
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All metabolic measurements, unless other specified were performed under ad lib feeding 
with consideration for diurnal metabolic effects. 
 
Caloric intake and body composition analysis.   
Body weight measurements were performed upon weaning and mice were weighed once 
per week.  Caloric intake in mice on chow diet (Figure 2B) was measured by weighing 
food once per day for a period of 3 days (N=10 per genotype).  Body composition in 
mice on chow diet (Figure 2C) was performed using dual-energy X-ray absorptiometry 
(DEXA) using a Piximus II (GE Healthcare Lunar) (numbers of mice used: FVB/N N=4, 
K5-UCP3 N=5).   
 
High fat diet studies.   
Mice used for diet studies were littermates weaned onto either control diet (D12450) or 
60% kcal high fat diet (D12492) both from Research Diets (New Brunswick, NJ). Body 
weight and caloric intake were measured once per week. (numbers of mice used:  FVB/N 
CD N=21, FVB/N HF N=19, K5-UCP3 CD N=20, K5-UCP3 HF N=14). Body 
composition analysis in mice on control and high fat diet was performed using an 
EchoMRI 100H (Houston, TX) (numbers of mice used:  FVB/N CD N=6, FVB/N HF 





Glucose and insulin Tolerance Tests.   
For glucose and insulin tolerance tests, mice were fasted overnight (14-16 hours) and 
fasting blood glucose measurements were taken using a TrueTrack® glucometer (Nipro 
Diagnostics, Fort Lauderdale, FL) via tail tip.  Mice were then given an intraperitoneal 
injection of either 2g/kg glucose or 0.75U/kg insulin and blood glucose levels were 
monitored via the tail tip over the period of 2-3 hours.  Area under the curve 
measurements were calculated using the trapezoid rule. (numbers of mice used:  GTT, 
FVB/N N=20, K5-UCP3 N=14, ITT, FVB/N N=5, K5-UCP3 N=5). 
 
Serum Insulin and NEFA levels.  
Fasting insulin and NEFA levels were measured in serum from overnight fasted (14-16 
hours) mice (N=5).  Mice were sacrificed by isoflurane exposure followed by cardiac 
puncture for blood collection.  Blood was allowed to coagulate at 4°C for 1-2 hours 
followed by centrifugation at 3000 x g for 15 minutes and serum was removed and flash 
frozen in liquid nitrogen and stored at -80°C until further analysis.  Fasting insulin levels 
were detected using an Insulin ELISA (EMD Millipore, Billerica, MA). 
 
Lactate Dehydrogenase Assay.  
Lactate secretion was measured from isolated primary keratinocytes using a lactate 
colorimetric assay (BioVision, Milpitas, CA).  Briefly, primary keratinocytes were 
isolated as described previously (full protocol in Appendix A) and grown in Eagle’s 
Minimal Essential Medium-2 (Invitrogen, Carlsbad, CA) supplemented with 1% FBS 
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(0.05mM Ca2+).  Lactate levels were measured in the media after 1 hour incubation with 
primary cells and normalized to total protein. 
 
Gene Expression in Epidermis.  
Epidermis was isolated from ad libitum fed mice and mice fasted 14-16 hours (full 
protocol in Appendix A). Briefly, mice were sacrificed via CO2 exposure followed by 
cervical dislocation, shaved on the dorsal surface followed by treatment with a depilatory 
agent.  Dorsal skin samples were excised, subcutaneous fat removed and discarded. 
Epidermal tissue was collected and flash frozen in liquid nitrogen and stored at -80°C 
until further analysis.  Tissue was ground under liquid nitrogen using a mortar and pestle 
and homogenized in TRI Reagent (Sigma-Aldrich, St. Louis, MO) with a dounce 
homogenizer.  RNA was extracted according to TRI reagent protocol and cDNAs were 
created using 2μg total RNA per reaction with MMLV-RT (Life Technologies, Grand 
Island, NY).  Real-time PCR was performed using iTaqΠ™ Universal SYBR® Green 
Supermix in a CFX96 Real-Time PCR Machine (Bio-Rad, Hercules, California). Primer 
sequences are listed in Appendix B. 
 
Immunoblotting.   
Epidermal tissue or whole cell lysates were prepared by lysis in RIPA buffer (50 mM 
Tris-HCl, 1% NP-40, 0.5% Na Deoxycholate, 0.1% SDS, 150 mM NaCl, 2 mM EDTA) 
supplemented with protease and phosphatase inhibitor cocktails (Roche, Nutley, NJ).  For 
membrane localization experiment, tissue fractionation was performed using differential 
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centrifugation and density gradients as described92. Protein lysates were separated by 
SDS-PAGE and transferred to nitrocellulose.  Blots were probed with the following 
primary antibodies: α-phospho Akt S473, α-phospho Akt T308, α-Akt, α-phospho 
FOXO1 S256, α-phospho FOXO1 S319, α-phospho GSK-3β S9, α-GSK-3β, α-phospho 
TSC2 S939, α-phospho mTOR S2448, α-phospho mTOR S2481, α-mTOR, α-phospho 
4EBP1 T36/47, α-4EBP1, α-phospho rs6 T240/244, α-rS6, α-phospho eIF4G S1108, α-
phospho EGFR Y1086, α-EGFR, α-phospho p38 MAPK T180/Y182, α-p38 MAPK, α-
PTEN, α-PP2Ac, α-PP2Aa, α-phospho ERK T202/Y204, α-ERK, α-phospho p90 RSK 
T359/S363, α-p90 RSK, α-β-Actin, (Cell Signaling Technology, Danvers, MA), α-
Cyclin D1, α-Cyclin A, α-p21, α-p27, α-α tubulin (Santa Cruz Biotechnology, Dallas, 
TX), α-α3 Integrin (Chemicon, Billerica, MA), and α-UCP3 (Washington 
Biotechnology, Simpsonville, MD).  Following primary antibody, blots were incubated 
with α-rabbit-HRP or α-mouse-HRP (GE Healthcare, Piscataway, NJ), and developed 
using chemiluminescent substrate (Thermo Scientific, Rockford, IL). Results are 
representative of three separate experiments. 
 
Metabolomic Analysis.   
For metabolic profiling, mice (n=6 per genotype) were fasted for 5 hours prior to sample 
collection to control for metabolic variation due to feeding, then sacrificed via cervical 
dislocation.  Dorsal skin biopsies were taken and epidermal tissue was harvested as 
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described above.  Samples were flash frozen in liquid N2 and stored at -80°C until 
processed. 
 
Unbiased metabolomic profiling analysis was performed by Metabolon (Durham, NC) as 
described elsewheret93.  Briefly, samples were prepared with the automated MicroLab 
STAR system from Hamilton Company using an aqueous methanol extraction process to 
remove proteins while allowing maximum recovery of small molecules.  Aliquots of the 
resulting extract were analyzed by ultrahigh performance liquid chromatography/mass 
spectrometry (UPLC/MS/MS; positive mode), UPLC/MS/MS (negative mode), or 
GC/MS.  Raw data were extracted, peak identified, processed against quality control 
standards, and normalized to total protein content by Metabolon.  Compounds were 
identified by comparison with a library of >2,400 purified standards’ analytical 
characteristics on Metabolon’s LC and GC platforms.   Compounds with a p-value <0.05 
in a Welch’s two-sample t-test were considered to be significantly different between 
genotypes. 
 
Tumor experiments.   
For Tg.AC tumor experiment, 16 week-old mice (Tg.AC n=20, K5-UCP3/Tg.AC n=20) 
were shaved dorsally and treated with biweekly applications of TPA (2.5 µg) for two 
weeks for a total of 4 treatments, as described elsewhere75.  For K5-UCP3/K5-Akt rescue 
experiment, adult (6-8-week) WT FVB/N (n=28) and hemizygous K5-UCP3 (n=27), K5-
Akt (n=29), and K5-UCP3/K5-Akt (n=18) littermates were initiated topically on shaved 
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dorsal skin with a single application of DMBA (100 µg) followed two weeks later with 
biweekly applications of TPA (2.5 µg) for 26 weeks, as previously described94.  In both 
experiments, mice were scored weekly for tumor incidence (percentage of mice with skin 
tumors) and tumor multiplicity (number of skin tumors per mouse).  Mice were sacrificed 
if moribund, if any individual tumor reached a diameter of >1 cm, or at the termination of 
the experiment.   
 
Topical treatments 
For all experiments involving topical application of chemicals, mice were shaved on 
dorsal skin 48 hours prior to treatment.  Two to four animals per group were used for 
each experiment.  Mice were treated topically with 200µL acetone (vehicle control), 12.5 
µg/mL TPA (2.5 µg dose), 25 mM OA (5 nmol dose), or 5 mg/mL Eto (1 mg dose) and 
sacrificed at the indicated time points.   
 
5-bromo-2-deoxyuridine (BrdU) labeling & histology 
24 hours after acetone or single TPA treatment, mice were injected i.p. with 10 mg/kg 
BrdU in sterile saline, then sacrificed 30 minutes after injection.  For 4x TPA treatment, 
mice received biweekly treatments for 2 weeks (total of 4 treatments), and were injected 
with BrdU and sacrificed 48 hours after the final TPA treatment.  Dorsal skin biopsies 
were collected and fixed overnight in 10% neutral buffered formalin, moved to 70% 
ethanol, and embedded in paraffin.  Sections were stained as previously described95.  
Labeling index was calculated as the percentage of basal epidermal cells positive for 
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BrdU.  >100 cells from 5 randomly selected skin sections (total >500 cells) were counted 
from each of n = 3 mice per genotype in each treatment group. 
 
PP2A activity assay 
PP2A was immuno-precipitated using primary α-PP2Ac (Millipore, Billerica, MA), 
incubated with a target phospho-peptide, and free phosphate release was measured via 
Malachite Green assay per the manufacturer’s instructions (Millipore, Billerica, MA). 
 
Primary cell cultures & signaling experiments 
All cell lines were cultured under standard conditions of 5% CO2, 37°C.  Primary mouse 
keratinocytes were harvested from the dorsal skin of adult mice and cultured as 
previously described96. For signaling experiments, cells were grown in EMEM-2 with 1% 
FBS for 48-72 hours following isolation, then starved overnight (~18 hours) before 
treatment. Primary neonatal human keratinocytes (NHK) were isolated as previously 
described97 and cultured in Keratinocyte Serum Free Media (KSFM, Life Technologies, 
Grand Island, NY) for no more than 5 passages. Transfections were performed using 
Lipofectamine 2000 reagent (Life Technologies, Grand Island, NY), and signaling 
experiments were performed 72 hours after transfection.  NHK were moved to KSFM 
without epidermal growth factor (EGF) and bovine pituitary extract (BPE) supplements 
18 hours prior to treatment with 40 ng/mL EGF (Gemini Bioproducts, West Sacramento, 
CA) or 0.0001% BSA (vehicle control, Fisher Scientific, Pittsburgh, PA), incubated at 
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37°C, 5% CO2 until the indicated time point, then harvested and used for 
immunoblotting as described below. 
 
Statistics.   
Data are expressed as mean ± SEM. Repeated measures experiments (weights per week, 
caloric consumption, GTT, and ITT) were analyzed using a two way ANOVA followed 
by Tukey’s post hoc analysis using GraphPad Prism. Gene expression analysis and diet 
experiments were also analyzed by two way ANOVA followed by Tukey’s post hoc 
while analysis between genotypes was performed using the student’s t-test. Statistical 
significance was determined by a p< 0.05. 
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Appendices 




Collagen Coating (store at 4°C) 
 
MCDB 151 -100mL: Irvine Sci (Catalog # 9061 or M6645) 
Fibronectin-1mg: Sigma (Catalog # F-4759) 
PureCol – 1mL: Inamed Biomaterials (Catalog # 5409) 
BSA-10mg: Sigma (Catalog # A-3156) 
HEPES- 1mL of 2M HEPES: Sigma (Catalog # H-9135) 
 
Trypsin (store at 4°C – invert before use) 
Gibco (catlog #15090-046); dilute 1:10 in PBS prior to use.  
 
22.5% Percoll (store at 4°C) 




10mL 1N NaCl (sterile) 
300mL PBS 
 
EMEM base medium (1L) 
 
 NaCl – 6.72 g 
 KCl – 398 mg 
 D-glucose – 1g 
 NaP04  monobasic – 126.5 mg 
 MgSO4 hexahydrate – 185 mg 
 Phenol Red – 10 mg 
 NaHCO3 – 2.25 g 
 L-Glutamine (200mM) – 10mL 
 MEM non-essential amino acids (100x Sigma) – 10mL 
 MEM amino acids (50x Sigma) – 20mL 
 MEM vitamins (100x Sigma) – 10mL 
 ddH20 – 950mL 
 
EMEM #2  Supplements 
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 Calcium chloride – 0.05mM final 
 EGF – 5ng/mL final 
 Ethanolamine – 10uM final  
 FBS – 1 % final 
 L-Glutamine -1mM final (not including what is in the base) 
 HEPES – 10mM final 
 Insulin – 5μg/mL 
 Penicillin/Streptomycin – 100U/mL 
 O-Phosphoethanolamine - 10μM 




1. Prepare sterile materials in the biosafety cabinet:  
 
a. Sterile forceps (2), scissors, #22/23 scalpel, polypropylene monofilament 
mesh (Small Parts Inc. catalog # CMP149-C) – 1 per genotype, small stir bars 
– 1 per genotype. 
b. 50mL beaker containing 30mL PBS + 1mL Pen/Strep – one per genotype 
c. plastic petri dishes (100mm) – one per mouse  
d. glass petri dishes (100mM) - one per 3 mice 
e. 1X trypsin (diluted PBS) – 15mL per glass dish 
 
2. Prepare materials outside of biosafety cabinet: 
  
 a. Large beaker with betadine (~100mL) 
 b. 70% ethanol – (~300mL for washing) 
 c. Clippers and Nair for hair removal 
  
3. Sacrifice mice and use clippers to remove dorsal hair then apply Nair for about 1 min.   
 
4. Wash the mouse with tap water to remove Nair and hair then place whole mouse in 
beaker with betadine.  Rinse mice with betadine and then with tap water until water is 
clear. 
 
5. Rinse mice twice with 70% ethanol (do not rinse with water after this). Dry animals 
with absorbent pad and transfer to the biosafety cabinet. 
6. Using sterile scissors and forceps remove dorsal skin from each mouse and place in 
beaker with PBS and Pen/Strep. Keep genotypes in separate beakers. 
 
7. One skin at a time, remove from PBS/Pen/Strep and place skin hair side down in a 
plastic petri dish.  Use scalpel to remove subcutaneous fat.  Make long consistent strokes 
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and scrape at a consistent depth across each piece of skin.  (It is important to remove all 
fat for subsequent steps) 
 
8. Transfer skin to a clean petri dish and place hair side up (flip the skin over).  Spread 
the skin out and allow to dry for 3-5 min.   
 
9. Transfer skin (still hair side up) to a glass petri dish containing 15mL 1X trypsin.  Skin 
should float on top of liquid. Avoid air bubbles between skin and trypsin and avoid 
trypsin on top of the skin samples.  Up to 3 skins can fit in one petri dish, keep genotypes 
separate. 
 
10. Place skins in incubator – time and temperature varies based on procedure: 
 
a. Oximetry in whole epidermis:  30°C for 1 hour and 30-45 minutes. Shorter 
times make collecting whole sheets of epidermis difficult, longer times reduce 
epidermal respiration and increase cell dissociation from epidermal sheet. 
 
b. Isolation of primary keratinocytes: 30°C for 2 hours or 1 hour at 37°C and one 
hour at room temperature.  Not much differs between theses methods in terms of 
efficiency.  2 hours at 37°C can decrease final cell yield. 
 
11. Remove skins from incubator and place in biosafety cabinet. Prop one edge of a petri 
dish up and add 4mL EMEM #2 (10% FBS) to the dish.  Lightly rinsing the petri dish 
with the media will allow the skin to slide, making it easier to handle.  Spread the skin 
out flat (hair side up) and use a scalpel to scrape epidermis off in sheets.  Collect 
epidermis in pooled media at the bottom of petri dish. Use the same dish for all skin from 
each genotype. 
 
12. Carefully transfer epidermis from perti dish into a 50mL beaker and rinse petri dish to 
collect remaining cells with 7mL EMEM #2 (10% FBS) and collect in beaker. 
 
13. Mince the epidermis with scissors for 5 minutes each. With 30mL EMEM #2 (10% 
FBS) rinse scissors and collect extra cells in 50mL beaker. Add small stir bar and cover 
beaker with sterile foil. Place beaker on stir plate and stir gently for 30 min.  
 
14. Filter samples through mesh using a sterile glass funnel into a 50mL conical tube.  
Spin cells at 250 x g for 10min at 4°C. 
 
15. Remove supernatant and resuspend pellets in 2mL EMEM #2 (10% FBS).  This is 
2mL/percoll gradient, no more than 6 mice should be used on a single percoll gradient. 
Resuspend this pellet well as a single cell suspension is best for the percoll gradient. 
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16. Add 20mL cold 22.5% percoll to a 50mL tube, overlay the cell suspension on the 
percoll by adding very slowly to the 50mL tube while at a 45 degree angle. 
 
17. Spin percoll gradient at 250 x g with slow acceleration and no break for 15 minutes at 
4°C.  Remove supernatant and take care not to disrupt the loose pellet. 
 
18.  Resuspend pellet in 10mL EMEM #2 (1% FBS) and then spin at 250 x g at 4°C and 
remove supernatant.  This step removes excess percoll.  Resuspend final pellet in EMEM 
#2 (1% FBS).  Resuspension volume can be anything less than 10mL. 
 
19. Count cells and plate on collagen coated plates. Wash cells with PBS and change 
media the next day to remove dead cells.  2-3 million cells per 6-well plate will  be 
confluent within 48-72 hours after initial plating. 
 
I. ISOLATION OF PRIMARY KERATINOCYTES FROM HUMAN FORESKIN SAMPLES  
Reagents: 
 
Keratinocyte Serum Free Media (Gibco) - supplemented with bovine pituitary extract and 
EGF. Store at 4°C. 
 
HBSS Solution – sterile 
 
 50mL HBSS (10x w/o Bicarb, Gibco #14060-057) 
 5mL 7% Sodium Bicarbonate (tissue culture grade) 
 5mL of 1M HEPES  
 440mL ddH2O 
 
Dispase Solution – filter sterilize and store at 4°C. 
  
 50mL HBSS Solution  
 5μl Gentamicin (50mg/mL stock - 5 μg/mL final) 
 2μ Fungizone (250μg/mL) 
 500mg Dispase (Final 10mg/mL) 
 
Stop Media – sterile, store at 4°C 
  
 DMEM culture media 
 10% FBS  
 1% Pen/Strep 
 0.1% Gentamicin 
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Preparation for sample collection: 
  
Place 5mL EMEM #2 media + 1:10,000 dilution of Gentamicin (50mg/mL) 




1. Use sterile scissors and forceps in a biosafety cabinet. 
 
2. Place 2-3mL Dispase Solution in 6-well plates. 
 
3. Place sample in petri dish and flatten out foreskin by trimming subcutaneous fat. If 
necessary, cut sample into pieces 1-2 cm pieces. 
 
4. Float flattened skin on dispase solution. Sample may curl under which is okay. 
 
5. Cover and place plates at 4°C overnight (16-18 hours), longer will decrease viability. 
 
6. Use sterile forceps in a biosafety cabinet.  Transfer skin to a petri dish and use forceps 
to peel epidermis from the dermis.  Place epidermis in a 50mL tube containing 2-3mL 
trypsin-EDTA (0.25% Trypsin, 1mM EDTA). Swirl to immerse tissue and place at 37°C 
for 5-7 minutes. Gently swirl half way through incubation. 
 
7.  Add 25-30mL Stop media, swirl to mix.  Centrifuge at 3000 x g for 10 minutes at 4°C. 
 
8. Remove supernatant along with any floating tissue.  Resuspend cells in 10mL KSFM. 
Resuspend very well as cell viability is increased when cells are plated in a single cell 
suspension. 
 
9. Plate cells in 10 cm dishes. One sample plated in a single 10 cm dish will usually be 
confluent in 1-2 days, samples can be spread between several 10 cm plates however 
lower levels of confluence will reduce the rate of proliferation of cells. 
 
Transfection of NHK cells: 
 
Cells are transfected in suspension so set up DNA complexes first and then split cells. 
Complexes will be ready by the time the cells are ready to plate. Transfections are 
described for 10cM plates transfected with 5-10μg DNA total and a lipofectamine:DNA 
ratio of 3:1. 
 
1. Pre-warm KSFM (no supplements) and bring all other reagents to room temperature. 
 
2. Prepare DNA stocks to 1 or 2μg/μl. 
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3. Dilute DNA in 500μl KSFM (no supplements), add lipofectamine 3000 and p3000 
reagent according to manufacturers recommendations. Allow DNA to complex at room 
temperature for 15-30 minutes. 
 
4. Plate cells 1.2-1.5 million cells per 10cm dish. Add complexed DNA dropwise and 
swirl plate to mix. Place plates in 37°C incubator. Remove media and wash cells with 
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